Relationship between HPV and the biomarkers annexin A1 and p53 in oropharyngeal cancer

Infectious Agents and Cancer

Amílcar Sabino Damazo¹  Egle Solito⁴  Cíntia Mara de Amorim Gomes Nakata³  Cleberson Jean dos Santos Queiroz² 

[1] Department of Basic Science in Health; Faculty of Medicine (FM), Federal University of Mato Grosso (UFMT), Mato Grosso, MT 78060-900, Brazil;Henry Wellcome Laboratory, University of Liverpool, 1st Floor, Nuffield Building, Liverpool L69 3GE, UK;Post-Graduation in Health Science, Faculty of Medicine (FM), Federal University of Mato Grosso (UFMT), Mato Grosso, MT 78060-900, Brazil;William Harvey Research Institute; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK

关键词: Oropharynx;    Cancer;    p53;    HPV;    Annexin A1;   

Others  :  800914
DOI  :  10.1186/1750-9378-9-13

 received in 2013-12-22, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

Human papillomavirus (HPV) is often present in oropharyngeal cancers. Head and neck tumors have been examined for other molecular markers including p53 and annexin A1 (ANXA1). Here, we investigated the prevalence of HPV and its relationship with p53 and ANXA1 in patients with oropharyngeal cancer.

Methods

We have analyzed tumor and adjacent mucosa from 22 patients with squamous cell carcinoma of the oropharynx in addition to samples of the oropharyngeal epithelium in subjects without cancer. We evaluated the presence of the HPV (subtypes 16/18 and 31/33) by chromogenic in situ hybridization. Additionally, we used immunofluorescence to examine the expression of p16, p53, ANXA1 and the phosphorylation of the ANXA1 residues Ser27 (ANXA1-SER) and Tyr21 (ANXA1-TYR).

Results

We have detected the presence of HPV genome in 59% of the 22 tumors. Of those, 92% were also positive for p16 immunostaining. Furthermore, we demonstrated a reduction in the expression of p53 in HPV + compared to HPV- tumors. Also, a reduction was observed in the expression of ANXA1 in tumors compared to epithelium from the margins and from controls. We also noted a reduction in ANXA1-TYR in tumors. However, the expression of both ANXA1 and ANXA1-SER were elevated in the margins of the HPV + versus HPV- tumors.

Conclusions

Our results confirm a high prevalence of HPV in oropharyngeal cancer and a reduction in p53 expression in HPV + tumors. We observed a hypoexpression of ANXA1 and ANXA1-TYR in oropharyngeal cancer. The increase in ANXA1-SER in the margins of HPV + tumors suggests that the epithelium in these cases had been activated by an infectious agent. Those findings indicate that ANXA1 and its phosphorylated forms can play important roles in the response to HPV infection and the carcinogenesis of the oropharynx.

【 授权许可】

   
2014 Queiroz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]Hilgert E, Bergmann C, Fichtner A, Gires O, Issing W: Tobacco abuse relates to significantly reduced survival of patients with oropharyngeal carcinomas. Eur J Cancer Prev 2009, 18(2):120-126.
• [3]Andrews E, Seaman WT, Webster-Cyriaque J: Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. Oral Oncol 2009, 45(6):486-491.
• [4]Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988, 48(11):3282-3287.
• [5]O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013, 31(5):543-550.
• [6]Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
• [7]Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008, 26(19):3128-3137.
• [8]Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
• [9]Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, Ramaekers FC, Hopman AH, Manni JJ: A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8. Int J Cancer 2003, 107(3):394-400.
• [10]Kuo KT, Hsiao CH, Lin CH, Kuo LT, Huang SH, Lin MC: The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome. Mod Pathol 2008, 21(4):376-386.
• [11]Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990, 249(4971):912-915.
• [12]Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990, 10(11):5772-5781.
• [13]Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352(6333):345-347.
• [14]Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992, 89(10):4495-4499.
• [15]Wang Y, Blandino G, Oren M, Givol D: Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998, 17(15):1923-1930.
• [16]Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445(7128):656-660.
• [17]Levine AJ, Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9(10):749-758.
• [18]Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP: p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991, 338(8765):513.
• [19]Flower RJ, Blackwell GJ: Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979, 278(5703):456-459.
• [20]Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE: The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 1999, 274(53):37620-37628.
• [21]Oliani SM, Perretti M: Cell localization of the anti-inflammatory protein annexin 1 during experimental inflammatory response. Ital J Anat Embryol 2001, 106(2 Suppl 1):69-77.
• [22]Damazo AS, Flower RJ, Solito E, Oliani SM: Annexin-A1 gene expression during liver development and post-translation modification after experimental endotoxemia. Inflamm Res 2008, 57(3):97-103.
• [23]Damazo AS, Yona S, Flower RJ, Perretti M, Oliani SM: Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol 2006, 176(7):4410-4418.
• [24]Croxtall JD, Flower RJ: Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci U S A 1992, 89(8):3571-3575.
• [25]Solito E, Kamal A, Russo-Marie F, Buckingham JC, Marullo S, Perretti M: A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 2003, 17(11):1544-1546.
• [26]Futter CE, White IJ: Annexins and endocytosis. Traffic 2007, 8(8):951-958.
• [27]Robinson-Bennett BL, Deford J, Diaz-Arrastia C, Levine L, Wang HQ, Hannigan EV, Papaconstantinou J: Implications of tyrosine phosphoproteomics in cervical carcinogenesis. J Carcinog 2008, 7:2. BioMed Central Full Text
• [28]Solito E, Christian HC, Festa M, Mulla A, Tierney T, Flower RJ, Buckingham JC: Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface. FASEB J 2006, 20(9):1498-1500.
• [29]Rothhut B: Participation of annexins in protein phosphorylation. Cell Mol Life Sci 1997, 53(6):522-526.
• [30]Wang W, Creutz CE: Regulation of the chromaffin granule aggregating activity of annexin I by phosphorylation. Biochemistry 1992, 31(41):9934-9939.
• [31]de Coupade C, Gillet R, Bennoun M, Briand P, Russo-Marie F, Solito E: Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. Hepatology 2000, 31(2):371-380.
• [32]Wang LP, Bi J, Yao C, Xu XD, Li XX, Wang SM, Li ZL, Zhang DY, Wang M, Chang GQ: Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma 2010, 57(3):253-259.
• [33]Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K: Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 2008, 25(7):695-702.
• [34]Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK: Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 2002, 8(1):117-123.
• [35]Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K, Hatanaka Y, Hatase O, Nishioka M: Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996, 24(1):72-81.
• [36]Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF, Zhao XH: Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004, 10(10):1466-1470.
• [37]Johnson MD, Kamso-Pratt J, Pepinsky RB, Whetsell WO: Lipocortin-1 immunoreactivity in central and peripheral nervous system glial tumors. Hum Pathol 1989, 20(8):772-776.
• [38]Ahn SH, Sawada H, Ro JY, Nicolson GL: Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 1997, 15(2):151-156.
• [39]Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT: Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 2006, 12(15):4598-4604.
• [40]Gillison ML, Castellsague X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, Arbyn M, Franceschi S: Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 2014, 134(3):497-507.
• [41]Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, Yi B, Xiao ZQ: Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008, 14(2):435-445.
• [42]Rodrigo JP, Garcia-Pedrero JM, Fernandez MP, Morgan RO, Suárez C, Herrero A: Annexin A1 expression in nasopharyngeal carcinoma correlates with squamous differentiation. Am J Rhinol 2005, 19(5):483-487.
• [43]Alves VA, Nonogaki S, Cury PM, Wünsch-Filho V, de Carvalho MB, Michaluart-Júnior P, Moyses RA, Curioni OA, Figueiredo DL, Scapulatempo-Neto C, Parra ER, Polachini GM, Silistino-Souza R, Oliani SM, Silva-Júnior WA, Nobrega FG, Tajara EH, Zago MA, Project/GENCAPO HaNG: Annexin A1 subcellular expression in laryngeal squamous cell carcinoma. Histopathology 2008, 53(6):715-727.
• [44]Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C, Rodrigo JP: Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004, 164(1):73-79.
• [45]Zhang L, Yang X, Zhong LP, Zhou XJ, Pan HY, Wei KJ, Li J, Chen WT, Zhang ZY: Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma. J Oral Pathol Med 2009, 38(4):362-370.
• [46]Calmon MF, Mota MT, Babeto E, Candido NM, Girol AP, Mendiburu CF, Bonilha JL, Silvestre RV, Rosa BM, Thomé JA, Medeiros GH, Soares FA, Guimarães GC, de Arruda JG, Oliani SM, Villa LL, Vassallo J, Rahal P: Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs. PLoS One 2013, 8(1):e53260.
• [47]Shimoji T, Murakami K, Sugiyama Y, Matsuda M, Inubushi S, Nasu J, Shirakura M, Suzuki T, Wakita T, Kishino T, Hotta H, Miyamura T, Shoji I: Identification of annexin A1 as a novel substrate for E6AP-mediated ubiquitylation. J Cell Biochem 2009, 106(6):1123-1135.
• [48]Aparna M, Shenai P, Chatra L, Veena KM, Rao PK, Prabhu RV, Shahin KA: Field cancerization: a review. Arch Med Health Sci 2013, 1(2):136.
• [49]Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev 2002, 82(2):331-371.
• [50]Radke S, Austermann J, Russo-Marie F, Gerke V, Rescher U: Specific association of annexin 1 with plasma membrane-resident and internalized EGF receptors mediated through the protein core domain. FEBS Lett 2004, 578(1–2):95-98.
• [51]Schaer DA, Lesokhin AM, Wolchok JD: Hiding the road signs that lead to tumor immunity. J Exp Med 2011, 208(10):1937-1940.
• [52]Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, Fridman WH, Tartour E: Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010, 32(7):946-958.
• [53]Blagosklonny MV: Loss of function and p53 protein stabilization. Oncogene 1997, 15(16):1889-1893.
• [54]Rowley H, Sherrington P, Helliwell TR, Kinsella A, Jones AS: p53 expression and p53 gene mutation in oral cancer and dysplasia. Otolaryngol Head Neck Surg 1998, 118(1):115-123.
• [55]Lecona E, Barrasa JI, Olmo N, Llorente B, Turnay J, Lizarbe MA: Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. Mol Cell Biol 2008, 28(15):4665-4674.
• [56]Doorbar J: The papillomavirus life cycle. J Clin Virol 2005, 32(Suppl 1):S7-15.
• [57]Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM: Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008, 14(2):366-369.
• [58]World Health Organization classification of tumours: Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005.
• [59]Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC: Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 2003, 144(4):1164-1174.